Frontiers in nuclear medicine · 2026
Incidental detection of PDAC via 18F-PSMA PET/CT in a patient with recurrent prostate cancer. A case report.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Savelli Giordano, Bonacina Mattia, Soffientini Alberto, Archiati Elvira, Bnà Claudio, Zaniboni Alberto
Аннотация
INTRODUCTION: Prostate specific membrane antigen (PSMA) is a type II transmembrane protein overexpressed in the neovasculature of some pancreatic ductal adenocarcinoma (PDAC). PET/CT can detect this expression and has now become an essential tool in this context. However, this antigen can also be expressed by other neoplasms. While this may create diagnostic uncertainty, it could also open therapeutic opportunities.
CLINICAL CASE: Here we describe a case in which a PET/CT performed to restage a patient with prostate adenocarcinoma experiencing biochemical recurrence revealed the coexistence of a PDAC.
LITERATURE REVIEW: A literature review aimed to summarize the bibliographic evidence on the use of this technique in this setting, which is relatively uncommon.
CONCLUSION: Prostate-specific membrane antigen can be overexpressed in PDACs. This finding may offer potential for theranostic applications.
CLINICAL CASE: Here we describe a case in which a PET/CT performed to restage a patient with prostate adenocarcinoma experiencing biochemical recurrence revealed the coexistence of a PDAC.
LITERATURE REVIEW: A literature review aimed to summarize the bibliographic evidence on the use of this technique in this setting, which is relatively uncommon.
CONCLUSION: Prostate-specific membrane antigen can be overexpressed in PDACs. This finding may offer potential for theranostic applications.